When Free 'Drug-Interaction Checker Mobile Apps' Ensure Interaction Free Medications for ICU Patients in Resource Limited Setups

2019 ◽  
Author(s):  
Md. Jahidul Hasan ◽  
Raihan Rabbani ◽  
Sitesh C. Bachar
2020 ◽  
Vol 12 (2) ◽  
Author(s):  
Md Jahidul Hasan ◽  
Raihan Rabbani ◽  
Sitesh C Bachar

Background: Critical care pharmacists (CCPs) have a key role in ensuring medication safety by screening drug-drug interactions (DIs) in polypharmacy prescriptions, mostly in critically ill patients. The drug-interaction checker mobile apps (DICMA) are freely available for smartphones. Objectives: The current study aimed to assess the utilization of smartphone-based free mobile apps by CCPs for ensuring drug-drug interaction-free polypharmacy prescriptions in critically ill patients. Methods: This observational study was conducted in an intensive care unit. Critical care pharmacists (CCPs) checked the medications of polypharmacy prescriptions to detect DIs or potential drug-drug interactions (PDIs) using free DICMA installed on their smartphones. DIs/PDIs were sent to physicians as suggestions, and the prescriptions were modified accordingly. Results: CCPs screened 2,967 prescriptions, where 11,128 and 3,932 DIs and PDIs were identified, respectively. Prescriptions with 6 to 10 medications and prescription with more than 10 medications, on average, had 3.28 and 7.53 DIs, respectively, and 1.42 and 4.7 PDIs, respectively. Physicians accepted 95.85% (n = 3,932) of PDI suggestions from CCPs and modified prescriptions, accordingly. CCPs reported a satisfaction level of 4 (on a scale of 5) concerning the use of free DICMA. Conclusions: Drug-drug interactions-free polypharmacy prescriptions can ensure medication safety in patients. CCPs are professionally responsible for this task, but resource-limited setups do not provide them scopes to accomplish this task efficiently. In this study, CCPs ensured medication safety in the prescriptions of critically ill patients efficiently using free DICMA installed on their smartphones.


Author(s):  
M Yulis Hamidy ◽  
Dina Fauzia

Objective:Drug interaction is one factor that contributes to drug-related problems. The hospitalized patients in intensive care units (ICU) have a higher risk for developing drug interactions. The purpose of this study was to evaluate the potency of significantdrug interactions in ICU patients.Methods:Drug-drug interactions from patient's medical records from ICU of Arifin Achmad General Hospital in Pekanbaru, Province of Riau, Indonesia at period July to December 2015 wereassessed. Drug Interaction Checker (Medscape) software was used to identify potential drug interactions.Results: This study included 28 ICU patients (mean age, 48 years) who had potency to drug interactions based on the software. Of these, 29% were male and 71% were female patients. The number of drugs that were given to patients was 3 to 13 drugs (average 7 drugs per patient). There were 122 potential drug-drug interactions found in this study, consisting of 43% potency of minor or non-significant, 52% potency of significant, 3% potency of serious, and 2% potency of contraindicated drug interactions. A total of 67% were pharmacodynamics and 33% were pharmacokinetics interactions. Dexamethasone, ketoprofen, ketorolac, furosemide, nifedipine, and enoxaparin were among drugs with highest frequency of potential drug interactions. Conclusion:Significant drug-drug interactions were prevalent in the ICU patients. This may be due to the complexity of the pharmacotherapies administered. The health professionals who provide care to these patients must be aware in order to identify and prevent possible drug events.  


2013 ◽  
Vol 27 (2) ◽  
pp. 214-216 ◽  
Author(s):  
Indira Valadê Carvalho ◽  
Renata Cavalcanti Carnevale ◽  
Marília Berlofa Visacri ◽  
Priscila Gava Mazzola ◽  
Rosiane de Fátima Lopes Ambrósio ◽  
...  

Introduction: There are no published reports on pediatric phenytoin toxicity, resulting from the drug interaction between phenytoin and valproic acid. Case description: A 12-year-old patient with refractory epilepsy syndrome presented with phenytoin toxicity, following a concomitant treatment with phenytoin, valproic acid, and lamotrigine. The phenytoin concentration detected in the capsules used by the patient was in accordance with the prescribed dose and was appropriate for the age and weight of the patient. However, a supratherapeutic phenytoin serum concentration was observed (21.92 µg phenytoin/mL of blood). Consequently, the phenytoin dose was reduced, and the patient was monitored; 24 hours later the patient did not present with any signs/symptoms of toxicity. Discussion: Despite the appropriate phenytoin concentration in the capsules, the patient presented with phenytoin toxicity. This toxicity likely resulted from the drug interaction between phenytoin and valproic acid that leads to phenytoin displacement from plasmatic proteins and inhibits phenytoin metabolism, thereby increasing the concentration of free drug in the serum.


2001 ◽  
Vol 120 (5) ◽  
pp. A581-A581
Author(s):  
T ANDERSSON ◽  
L ASTRAZENECA ◽  
K ROHSS ◽  
M HASSANALIN

1998 ◽  
Vol 5 (1) ◽  
pp. 195A-195A
Author(s):  
K MCNAMARA ◽  
R BAJAJ ◽  
C ANANTH ◽  
S HATANGADI ◽  
J SMULIAN ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document